TG THERAPEUTICS, INC. cotiza a 55.27 USD y tiene una capitalización bursátil de $8.5B. En los últimos 12 meses ha facturado $800M con un margen de flujo de caja libre del -4.0%. Cotiza a 486.6 veces su flujo de caja libre (P/FCF) y a un PER de 19.2. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patient…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.05 | $0.18 | $0.14 |
| Estimado | $0.26 | $0.44 | $0.28 | $0.33 |
| Sorpresa | — | -88.6% | -35.7% | -57.6% |
| Métrica | TGTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 83.7% | 57.0% | +26.6% |
| Operating Margin | 20.0% | -38.6% | +58.6% |
| Net Margin | 72.6% | -33.6% | +106.1% |
| FCF Margin | -4.0% | -13.9% | +9.8% |
| ROE | 69.0% | -40.4% | +109.4% |
| ROA | 42.1% | -32.0% | +74.1% |
| Current Ratio | 4.10 | 2.84 | +1.26 |
| Debt / Equity | 0.38 | 0.28 | +0.10 |